Treatment results and patient characeristics for breast cancer patients older than 70 Years

Main Article Content

Gulçin Ertaş
Fatih Karatas
Ali Riza Üçer
Güçlü Sezai Kılıçoğlu
Muzaffer Bedri Altundağ


Objective: The incidence of breast cancer (BC) subtypes varies according to age, and its treatment is more strenuous and requires much more attention in advanced ages. The aim of this study is to investigate patient characteristics and treatment results respectively for patients older than 70 years.

Materials and Methods: In this study, we examined 188 elderly BC patients treated in our hospital, at March 2008 - November 2019. Patient characteristics and demographics were investigated from patients’ files retrospectively. 

Results: Mean age of the patients was 74.3 ± 4 years (All female). The presence of comorbid diseases was 76.1%. Major histology was invasive ductal carcinoma in 72.9% and mostly grade 2 differentiated, and the majority of patients were T2 size (58.5%). Oestrogen receptor (OR) positivity was seen in 83%, Progesterone receptor (PR) positivity in 72.3% of patients and cerb2 positivity in 16.5%. Luminal B (47.9%) was the most common in molecular subgroup analysis. Patients with lymph node involvement (N1 33%; N2, 19.1%; N3, 6.9%) were higher than those without involvement (34%). Surgery type was modified radical mastectomy (MRM) for 51.6%, breast conserving surgery (BCS) for 39.4 % and lumpectomy for 7.4%. In a median follow-up time was 53.9 (9-101) months, local recurrence was seen in 5 (2.7%) patients and distant metastasis was developed in 16 (8.5%) patients. The median overall survival was worse in those with MRM than those with BSC (p=0.006). In multivariate logistic regression analysis, only found that lymph node positivity was an independent risk factor for metastasis (HR; 4.15, 95% CI:1.019-16.933, P=0.047).

Conclusion: While it was observed that the most important risk factor for metastasis risk in elderly patients was lymph node positivity; The hormonal status and her2 conditions were not affected in terms of metastasis. It was thought that tumor clinical course and relapse may differ in the elderly population compared to general BC patients.


Download data is not yet available.

Article Details

How to Cite
Ertaş, G., Karatas, F., Üçer, A. R., Kılıçoğlu, G. S., & Altundağ, M. B. (2022). Treatment results and patient characeristics for breast cancer patients older than 70 Years. Medical Science and Discovery, 9(3), 143–148.
Research Article
Received 2022-02-05
Accepted 2022-03-01
Published 2022-03-01


Todua F, Gagua R, Maglakelidze M, Maglakelidze D. Cancer incidence and mortality-Major patterns in GLOBOCAN 2012, worldwide and Georgia. Bull Georg Natl Acad Sci. 2015;9(1):168-73.

Königsberg R, Pfeiler G, Hammerschmid N, Holub O, Glössmann K, Larcher-Senn J, Dittrich C. Breast cancer subtypes in patients aged 70 years and older. Cancer Investigation. 2016 May 27;34(5):197-204.

Gal O, Ishai Y, Sulkes A, Shochat T, Yerushalmi R. Early breast cancer in the elderly: characteristics, therapy, and long-term outcome. Oncology. 2018;94(1):31-8.

Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. Journal of Clinical Oncology. 2010 Apr 20;28(12):2038.

Lee CM, Zheng H, Tan VK, Tan TJ, Kanesvaran R, Wong FY, Sim YR, Yong WS, Madhukumar P, Ong KW, Tan BK. Surgery for early breast cancer in the extremely elderly leads to improved outcomes–an Asian population study. The Breast. 2017 Dec 1;36:44-8.

Chatzidaki P, Mellos C, Briese V, Mylonas I. Perioperative complications of breast cancer surgery in elderly women (≥ 80 years). Annals of surgical oncology. 2011 Apr;18(4):923-31.

Lee CM, Tan VK, Tan BK, Madhukumar P, Yong WS, Wong CY, Ong KW. Perioperative outcomes of therapeutic breast surgery in the elderly. Annals of the Academy of Medicine, Singapore. 2016 Jun;45(6):261-3.

Evron E, Goldberg H, Kuzmin A, Gutman R, Rizel S, Sella A, Gutman H. Breast cancer in octogenarians. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Apr 15;106(8):1664-8.

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The lancet oncology. 2012 Apr 1;13(4):e148-60.

Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Journal of British Surgery. 2004 Jun;91(6):699-704.

Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer—final results at 20-year follow-up. Critical reviews in oncology/hematology. 2011 Jun 1;78(3):260-4.

Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, Agresti R. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Annals of surgical oncology. 2011 Jan;18(1):125-33.

Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. Journal of geriatric oncology. 2017 Mar 1;8(2):140-7.

Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M. International Breast Cancer Study Group: Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol. 2006 Jan 20;24(3):337-44.

Martelli G, Boracchi P, Ardoino I, Lozza L, Bohm S, Vetrella G, Agresti R. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Annals of surgery. 2012 Dec 1;256(6):920-4.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The lancet oncology. 2010 Oct 1;11(10):927-33.

Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN evaluation with survival in women aged 70 years or older with clinically node-negative hormone receptor positive breast cancer. Annals of Surgical Oncology. 2017 Oct;24(10):3073-81.

Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine. 2004 Sep 2;351(10):971-7.

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. Journal of clinical oncology. 2013 Jul 1;31(19):2382.

Russell NS, Kunkler IH, van Tienhoven G, Canney PA, Thomas J, Bartlett J, van de Vijver MJ, Belkacemi Y, Yarnold JR, Barrett-Lee PJ. Postmastectomy radiotherapy: will the selective use of postmastectomy radiotherapy study end the debate?. Journal of Clinical Oncology. 2009 Feb 20;27(6):996-7.

Kunkler IH, Williams LW, Jack W, Canney P, Prescott RJ, Dixon MJ. Abstract S2-01: The PRIME II trial: Wide local excision and adjuvant hormonal therapy±postoperative whole breast irradiation in women≥ 65 years with early breast cancer managed by breast conservation. Abstract S2-01 presented at the San Antonio Breast Cancer Symposium; San Antonio, TX, USA. December 10–14, 2013

Tsai HT, Isaacs C, Fu AZ, Warren JL, Freedman AN, Barac A, Huang CY, Potosky AL. Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study. Breast cancer research and treatment. 2014 Feb;144(1):163-70.

Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal of clinical oncology. 2013 Nov 20;31(33):4222.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals of oncology. 2012 Apr 1;23(4):897-902.

Adamo V, Ricciardi GR, Adamo B, Ferraro G, Franchina T, Rossello R, Zanghì M, Cicero G, Rizzo S, Caristi N, Russo A. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology. 2014;86(1):16-21.

Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. Journal of clinical oncology. 2008 Apr 20;26(12):1972-9.

Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic Review of Bone Health in Older Women Treated with Aromatase Inhibitors for Early‐Stage Breast Cancer. Journal of the American Geriatrics Society. 2012 Sep;60(9):1761-7.

Fontein DB, Seynaeve C, Hadji P, Hille ET, Van De Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. Journal of Clinical Oncology. 2013 Jun 20;31(18):2257-64.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA. Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine. 2009 May 14;360(20):2055-65.

Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. Jama. 2006 Feb 15;295(7):801-8.

Cappellani A, Vita MD, Zanghì A, Cavallaro A, Piccolo G, Majorana M, Barbera G, Berretta M. Prognostic factors in elderly patients with breast cancer. BMC surgery. 2013 Oct;13(2):1-2.

Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005 May 14;365(9472):1687-717.

Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H. Adjuvant chemotherapy in older and younger women with lymph node–positive breast cancer. Jama. 2005 Mar 2;293(9):1073-81.